T2加权成像靶环样表现及肿瘤血管受累征象:鉴别肝细胞癌与其他原发性肝癌的诊断价值
这项在两家肝移植中心开展的回顾性研究纳入375例病理证实的肝脏病变(165例肝内胆管癌、74例混合型肝细胞-胆管癌及136例肝细胞癌对照),由两名腹部放射科医师独立评估T2加权成像靶环样表现及肿瘤血管受累征象。结果显示这些征象诊断非肝细胞癌原发性肝癌的特异度高(92-100%),但敏感度较低;在具有肝细胞癌危险因素的患者中,血管受累征象敏感度进一步降低(1.7-20.3%)而特异度升高至94.2%以上。
要点
- T2加权成像靶环样表现诊断非肝细胞癌原发性肝癌的敏感度为27.5%-32.6%,特异度为97.3%-98.2%。
- 肿瘤血管受累征象中,血管包绕和闭塞的敏感度相对较高,而血管牵拉和闭塞的特异度最高(达97.1%-100%)。
- 在具有肝细胞癌危险因素的患者中,血管受累征象敏感度降至1.7%-20.3%,特异度升至94.2%以上。
核心结论
- T2加权成像靶环样表现和肿瘤血管受累征象对诊断非肝细胞癌原发性肝癌具有高特异度。
研究设计与样本
- 经IRB批准的回顾性研究,在两家肝移植中心进行,纳入2007年至2017年间经病理证实的375例肝脏病变患者(165例肝内胆管癌、74例混合型肝细胞-胆管癌、136例肝细胞癌对照),采用增强CT(112例)或MRI(263例),由两名腹部放射科医师独立评估。
关键影像表现/征象
- T2加权成像上靶环样表现:诊断非肝细胞癌原发性肝癌的敏感度R1为27.5%、R2为32.6%,特异度R1为98.2%、R2为97.3%。
- 肿瘤血管受累征象中敏感度最高者为血管包绕(R1:34.3%;R2:37.2%)和闭塞(R1:25.5%;R2:29.7%)。
- 特异度最高者为血管牵拉(R1:100%;R2:97.1%)和闭塞(R1:99.3%;R2:99.3%)。
- 读者间一致性为中等至高度(k=0.48-0.77);T2加权成像靶环样表现的读者间一致性为高度(k=0.74)。
诊断标准与关键数值
- T2加权成像靶环样表现诊断非肝细胞癌原发性肝癌的敏感度27.5%-32.6%,特异度97.3%-98.2%。
- 血管包绕诊断非肝细胞癌原发性肝癌的敏感度R1为34.3%、R2为37.2%;血管闭塞敏感度R1为25.5%、R2为29.7%。
- 血管牵拉诊断非肝细胞癌原发性肝癌的特异度R1为100%、R2为97.1%;血管闭塞特异度R1和R2均为99.3%。
- 在具有肝细胞癌危险因素的患者亚组中,肿瘤血管受累征象的敏感度两名读者均为1.7%-20.3%,特异度升至94.2%以上。
- T2加权成像靶环样表现和肿瘤血管受累征象诊断非肝细胞癌原发性肝癌的特异度为92%-100%,不受肝病危险因素存在与否影响。
临床应用与阅片要点
- 阅片时可关注T2加权成像上的靶环样表现及肿瘤血管受累征象(包绕、狭窄、牵拉、闭塞、消失),这些征象对非肝细胞癌原发性肝癌具有高特异度。
- 在具有肝细胞癌危险因素的患者中,肿瘤血管受累征象的敏感度降低而特异度升高,判读时需结合临床背景。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate targetoid appearance on T2-weighted imaging and signs of tumor vascular involvement as potential new LI-RADS features for differentiating hepatocellular carcinoma (HCC) from other non-HCC primary liver carcinomas (PLCs).
METHODS: This IRB-approved, retrospective study was performed at two liver transplant centers. The final population included 375 patients with pathologically proven lesions imaged between 2007 and 2017 with contrast-enhanced CT or MRI. The cohort consisted of 165 intrahepatic cholangiocarcinomas and 74 combined hepatocellular-cholangiocarcinomas, with the addition of 136 HCCs for control. Two abdominal radiologists (R1; R2) independently reviewed the imaging studies (112 CT; 263 MRI) and recorded the presence of targetoid appearance on T2-weighted images and features of tumor vascular involvement including encasement, narrowing, tethering, occlusion, and obliteration. The sensitivity and specificity of each feature were calculated for the diagnosis of non-HCC PLCs. Cohen's kappa (k) test was used to assess inter-reader agreement.
RESULTS: The sensitivity of targetoid appearance on T2-weighted images for the diagnosis of non-HCC PLCs was 27.5% and 32.6% (R1 and R2) and the specificity was 98.2% and 97.3% (R1 and R2). Among the features of tumor vascular involvement, those providing the highest sensitivity for non-HCC PLCs were vascular encasement (R1: 34.3%; R2: 37.2%) and obliteration (R1: 25.5%; R2: 29.7%). The highest specificity for non-HCC PLCs was provided by tethering (R1: 100%; R2: 97.1%) and occlusion (R1: 99.3%; R2: 99.3%). The inter-reader agreement was moderate to substantial (k = 0.48-0.77).
CONCLUSIONS: Targetoid appearance on T2-weighted images and features of tumor vascular involvement demonstrated high specificity for non-HCC malignancy.
KEY POINTS: • Targetoid appearance on T2-weighted imaging and signs of tumor vascular involvement have high specificity (92-100%) for the diagnosis of non-HCC PLCs, regardless of the presence of liver risk factors. • In the subset of patients with risk factors for HCC, the sensitivity of signs of tumor vascular involvement decreases for both readers (1.7-20.3%), while the specificity increases reaching values higher than 94.2%. • The inter-reader agreement is substantial for targetoid appearance on T2-weighted images (k = 0.74) and moderate to substantial for signs of tumor vascular involvement (k = 0.48-0.77).
引用
- Cannella R, Fraum TJ, Ludwig DR, et al. Targetoid appearance on T2-weighted imaging and signs of tumor vascular involvement: diagnostic value for differentiating HCC from other primary liver carcinomas. Eur Radiol. 2021. PMID: 33590319. doi:10.1007/s00330-021-07743-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。